More recently, the 2022 International Consensus Classification stated that patients with RUNX1 mutations fit in the entity of AML with myelodysplasia-related gene mutations and remain in the adverse risk group [5]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.